Pharmacogenomics Journal

Papers
(The TQCC of Pharmacogenomics Journal is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data55
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data41
Economic evaluation in psychiatric pharmacogenomics: a systematic review35
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs30
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy22
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study21
Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis20
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection18
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience18
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle17
Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan16
Does the RAAS play a role in loss of taste and smell during COVID-19 infections?15
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review14
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States14
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis13
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders13
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review12
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model11
The variants at FLNA and FLNB contribute to the susceptibility of hypertension and stroke with differentially expressed mRNA10
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals10
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis10
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel10
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore10
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer10
CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice9
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors9
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-199
Using ChatGPT to predict the future of personalized medicine9
Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder8
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment8
Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients8
Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients7
Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis7
A blockchain-based framework to support pharmacogenetic data sharing7
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers7
New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin7
HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure7
A review of the existing literature on buprenorphine pharmacogenomics7
Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes7
0.067378997802734